Introduction
Obesity is frequently associated with metabolic syndrome, a disease state that includes glucose intolerance, insulin resistance, hypertension, hypertriglyceridemia, low level of high-density lipoprotein cholesterol (HDL-C), and type 2 diabetes mellitus (T2DM)[1]. Low-grade inflammation is associated with insulin resistance and precedes the onset of T2DM in obese individuals[3]. Adipose tissue is an important endocrine organ that regulates the insulin sensitivity of other peripheral insulin target tissues[3]. Excess adipose tissue, especially in the visceral compartment, results in excess secretion of peptide hormones and cytokines, which leads to whole-body insulin resistance and predisposes to T2DM[4].

Tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), and monocyte chemotactic protein 1 (MCP-1) are some of the inflammatory signaling molecules that may contribute to insulin resistance. TNF-α may enhance Ser\(^{307}\) phosphorylation of insulin receptor substrate 1 (IRS-1) proteins or other downstream effectors of the insulin signaling cascade that play negative regulatory roles in insulin action. Serine phosphorylation impairs insulin-stimulated tyrosine phosphorylation of IRS proteins, uncouples insulin signal transduction, and has been implicated in the development of insulin resistance[5–7].

Previously, Hong[8] implicated the signaling pathway of the transcription factor, nuclear factor κB (NF-κB), in the induction of insulin resistance. I-kappa-B (IκB) kinase (IKK) plays an important role in this pathway. IKKs, together with their upstream activating kinases, mediate signaling to NF-κB from a diverse array of stimuli, including TNF-α. TNF-α activates IKKs, which can in turn phosphorylate IκB (the inhibitors of NF-κB) and activate NF-κB. Increased NF-κB activity up-regulates multiple inflammatory factors that aggravate insulin resistance[8].

Statins, the inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMG-CoA) appear to have a number of potentially beneficial effects[9], some of which are indepen-
dent of their cholesterol-lowering effect. Some effects include improved endothelial function, anti-thrombotic and anti-proliferative effects, stabilization of atherosclerotic plaque, anti-cancer and anti-oxidant effects, and anti-inflammation. Regarding anti-inflammatory activity, statins may down-regulate activation of NF-κB in human endothelial and vascular smooth muscle cells[23]. By reducing the activity of this stimulator of IKK signaling, the anti-inflammatory consequences of statins may have benefits in insulin resistance. Therefore, we investigated the effects of atorvastatin, an HMG-CoA reductase inhibitor, on insulin resistance, glucose concentration, and lipid levels in an insulin-resistant mouse model of obesity.

**Materials and methods**

**Reagents**

Atorvastatin was obtained from Aifeimu Chemical Co (Zhejiang, China). Monosodium glutamate (MSG) was obtained from Huaboyuan Technologic Development Center (Beijing). RNAin protection liquid was from Appygen Technologies (Beijing). TRIzol reagent, random hexamer primers, and Superscript II reverse transcriptase were obtained from Invitrogen (Carlsbad, CA). Primary antibodies for NF-κB p65 and IκB-α were from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). All other regents used in this paper were from Sigma Aldrich (St Louis, MO).

**Animals and experimental protocol**

Pregnant ICR mice were purchased from the Experimental Animal Center, Chinese Academy of Medical Sciences (Beijing), and cared for in accordance with the standards for laboratory animals established by the People’s Republic of China (GB14925-2001). Monosodium glutamate (MSG) was subcutaneously injected in neonatal mice at 4 g/kg body weight once daily for 7 consecutive days after birth to induce obesity. Only mice with impaired insulin tolerance were used in this study[12]. Female and 6 months mice were divided into two groups (n=8 mice each) for treatment with vehicle (water) or atorvastatin (80 mg/kg), by oral administration. Treatment was given orally for 30 consecutive days, and mice underwent an insulin tolerance test (ITT) and oral glucose tolerance test (OGTT) and monitoring for plasma levels of cholesterol and triglycerides. On the last day of the experiment, mice were sacrificed by decapitation. Plasma was collected for assay. The concentrations of TNF-α and IL-6 in plasma and adipose tissue were measured with a radioimmunoassay kit (North TZ-Biotech, Beijing).

**Insulin resistance and insulin sensitivity index calculations**

The homeostasis model assessment was used to calculate the insulin resistance (HOMA-IR) index and insulin sensitivity index (ISI) using the values of fasting plasma glucose (FPG) and PI as follows: ISI=1/(FPG×PI)×1000, with FPG expressed as mg/dL and PI as mU/L; HOMA-IR=FPG×PI/22.5, with FPG expressed as mmol/L and PI as mU/L.

**RNA preparation and semi-quantitative RT-PCR**

Total RNA was isolated from mouse adipose tissue with TRIzol reagent (Invitrogen, Carlsbad, CA). First-strand cDNA was synthesized from 5 μg of total RNA with random hexamer primers and Superscript II reverse transcriptase (Invitrogen). The reaction mixture was amplified with primers specific for inflammatory factors and proteins (Table 1) in a total volume of 20 μL. Linearity of the PCR amplification was tested with amplification cycles between 32 and 40. The PCR products were analyzed on a 2% agarose gel, and the intensity of the corresponding bands was determined using a Kodak image station 440CF and 1D image analysis software (Eastman Kodak; Rochester, NY). mRNA expression of the genes was normalized to that of GAPDH[23].

**Adipose tissue homogenization and Western analysis**

Adipose tissue samples were homogenized in ice-cold buffer containing 50 mmol/L HEPES (pH 7.6), 150 mmol/L sodium chloride, 20 mmol/L beta-glycerophosphate, 10 mmol/L sodium fluoride, 2 mmol/L EDTA, 10% glycerol, 1 mmol/L magnesium chloride, 1 mmol/L calcium chloride, 10 μg/mL leupeptin, and 10 μg/mL aprotinin. Tissue homogenates were clarified by centrifugation at 14000×g for 15 min, and protein concentrations in the supernatant were determined with a
Bradford assay. Proteins in the supernatants of the tissue homogenates were resolved by SDS-PAGE and transferred to PVDF membrane. Bound proteins were blocked with 1% nonfat dry milk in Tris-buffered saline with 0.1% Tween 20, and probed with specific primary antibodies (NF-κB p65 and IκB-α from Santa Cruz). The membranes were washed with Tris-buffered saline with 0.5% Tween 20, then incubated with horseradish peroxidase-conjugated secondary antibody (Pro- mega Corp, Madison, WI). Proteins were visualized by chemiluminescence reactions, and the intensity of the corresponding bands was analyzed with a Kodak image station 440CF and 1D image analysis software (Eastman Kodak). The expression of proteins was normalized to that of GAPDH[14].

**Statistical analysis**
Results are presented as means±SEM. Statistical significance of differences was assessed by ANOVA, followed by the t-test. P<0.05 was considered statistically significant. All analyses were performed using SPSS version 13.0.

**Results**

**Insulin tolerance**
Plasma glucose levels after insulin injection were significantly lower in the obese mice treated with atorvastatin (80 mg/kg) than those in the vehicle-treated control obese mice at all times tested. As shown in Figure 1B the mean AUC for glucose was significantly reduced after atorvastatin treatment, compared to the control treatment (n=8, P<0.01, Figure 1).

**Oral glucose tolerance**
Compared to the control treatment, atorvastatin treatment produced lower blood glucose concentrations before and 30, 60 and 120 min after glucose loading (Figure 2A), and reduced the mean glucose AUC (Figure 2B).

**Effect of atorvastatin on plasma lipid profile**
On day 12, obese mice treated with atorvastatin showed significantly lower plasma levels of total cholesterol, LDL-C and HDL-C than the control obese mice (P<0.01). The atorvastatin treated mice also had markedly lower levels of triglycerides and FFAs (P<0.05, Table 2).

**Characteristics of MSG-induced obese mice**
The physical characteristics of the normal non-obese mice and the obese mice treated with either atorvastatin or vehicle control are shown in Table 3. Normal non-obese mice were lean and had a smaller waistline circumference, body weight and smaller waistline index than MSG-induced obese mice treated with vehicle control (P<0.01). Vehicle control-treated obese mice had more intraperitoneal fat and a greater intraperitoneal fat index than did non-obese mice (P<0.01). Atorvastatin treatment had no effect on body weight, body length, waistline, or intraperitoneal fat weight and index as compared with vehicle control treatment in obese mice.

**Effect of atorvastatin on inflammatory factors in plasma and adipose tissue**
The concentrations of IL-6 and TNF-α in serum and adipose
The serum concentration of IL-6 and TNF-α in vehicle control-treated obese mice was similar to that in normal non-obese mice. The atorvastatin-treated obese mice showed no difference in content from the vehicle-control treated obese mice. The adipose-tissue concentrations of IL-6 and TNF-α were significantly greater in vehicle-treated control obese mice than in normal non-obese mice \((n=8, P<0.01)\). Thirty-day atorvastatin treatment produced significantly lower adipose-tissue concentrations of IL-6 and TNF-α compared to vehicle control treatment in the obese mice \((n=8, P<0.05)\).

**Homeostasis model assessment of insulin resistance (HOMA-IR) index and insulin sensitivity index (ISI)**

The calculated values for the insulin resistance index and insulin sensitivity index are shown in Table 5. Fasting serum insulin levels were significant higher in vehicle-treated control obese mice than in normal non-obese mice. The HOMA-IR index was also higher in vehicle-treated control mice than in normal non-obese mice \((n=8, P<0.001)\). The ISI for vehicle-treated control mice was lower than that for normal non-obese mice \((n=8, P<0.001)\). Atorvastatin treatment decreased the HOMA-IR index and increased the ISI compared to vehicle control treatment in obese mice \((P<0.05, P<0.01, \text{respectively})\) (Table 5).

**Semi-quantitative RT-PCR analysis of inflammatory factors**

A semi-quantitative analysis of the expression of factors involved in inflammation pathways are shown in Figure 3. The expression of TNF-α and IL-6 was higher in the vehicle-treated control obese mice than in normal non-obese mice (Figure 3B, 3C), and the expression of IκB was lower in vehicle-treated control mice than in normal non-obese mice (Figure 3E). Atorvastatin treatment decreased the expression of TNF-α, IL-6, NF-κB, and IKK-β \((P<0.01, P=0.08, P<0.05, P<0.01, \text{respectively})\) and enhanced the expression of IκB.

---

Table 2.

| Group               | Triglycerides (mg/dL) | Total cholesterol (mg/dL) | LDL-C (mg/dL) | HDL-C (mg/dL) | Free fatty acids (μEq/L) |
|---------------------|-----------------------|---------------------------|--------------|--------------|--------------------------|
| Control             | 79.9±5.1              | 103.9±7.8                 | 16.7±1.0     | 77.7±6.4     | 415.7±15.9               |
| Atorvastatin (80 mg/kg) | 63.8±4.1\textsuperscript*b* | 59.3±5.4\textsuperscript*c* | 10.4±0.8\textsuperscript*c* | 37.5±2.9\textsuperscript*c* | 352.0±24.3\textsuperscript*b* |

LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.

Table 3.

| Group               | Body weight (g) | Body length (cm) | Waistline (cm) | Intraperitoneal fat (g) | Waistline index | Intraperitoneal fat index |
|---------------------|-----------------|-----------------|----------------|-------------------------|----------------|---------------------------|
| Normal non-obese    | 30.7±2.4        | 10.1±0.3\textsuperscript*c* | 8.73±0.42\textsuperscript*c* | 0.600±0.100\textsuperscript*c* | 0.86±0.062\textsuperscript*c* | 0.02±0.003\textsuperscript*c* |
| Control             | 63.0±7.5        | 10.9±0.5        | 13.24±0.77     | 6.650±1.753            | 1.21±0.090     | 10.54±2.416               |
| Atorvastatin (80 mg/kg) | 59.7±6.2        | 10.5±0.3        | 12.80±0.85     | 6.600±1.125            | 1.22±0.077     | 11.05±1.413               |

Waistline index = waistline circumference/body length. Intraperitoneal fat index is intraperitoneal fat/body weight.
(P=0.08) compared to vehicle control treatment in obese mice (Figure 3).

**Western blot analysis of NF-κB p65 and IκB-α**

The level of NF-κB p65 and IκB-α proteins were analyzed by Western blot analysis, and the results shown in Figure 4. The protein level of NF-κB was higher in vehicle treated control obese mice than in normal non-obese mice. Atorvastatin treatment reduced the protein level of NF-κB in obese mice compared to vehicle-treated control mice (P<0.05, Figure 4A, 4B). The level of IκB-α protein was lower in vehicle treated controls than in normal non-obese mice, and atorvastatin treatment enhanced the protein expression of IκB-α in obese mice (P<0.05, Figure 4A, 4C).

Table 4. Effect of atorvastatin on levels of TNF-α and IL-6 in MSG-induced obese mice with insulin resistance. Data are mean±SEM. Mice were treated with atorvastatin for 30 days. n=8 mice/group.  aP>0.05, bP<0.05, cP<0.01 vs control-treated obese mice.

| Group                      | Serum IL-6 (ng/mL) | IL-6 in adipose tissue (ng/mg protein) | Serum TNF-α (ng/mL) | TNF-α in adipose tissue (ng/mg protein) |
|----------------------------|--------------------|---------------------------------------|--------------------|----------------------------------------|
| Normal non-obese           | 0.096±0.007        | 0.127±0.025                           | 1.21±0.071         | 1.44±0.029                             |
| Control                    | 0.091±0.007        | 0.341±0.039                           | 1.19±0.039         | 3.79±0.062                             |
| Atorvastatin (80 mg/kg)    | 0.069±0.007        | 0.232±0.032                           | 1.34±0.025         | 2.20±0.021                             |
Insulin resistance is the critical pathological feature of type 2 diabetes mellitus, obesity, metabolic syndrome, and aging [15]. Although the precise pathogenesis of insulin resistance remains ill-defined, several factors have been proposed to have a role in this process, such as adipokines, defects in the insulin signaling pathway, mitochondrial dysfunction and inflammation [16, 17]. In the past few years it has been shown clearly that obesity, along with diabetes, is characterized by a state of chronic low-grade inflammation [18–20], implying that approaches designed to improve state of chronic low-grade inflammation should be useful in attenuating insulin resistance with obesity.

The effects of statins on insulin sensitivity had been reported in the past years, simvastatin and atorvastatin may improve insulin sensitivity in diabetic patients [21]; however, others have reported that simvastatin either did not change or worsened insulin sensitivity in diabetic patients [22, 23]. And there are no reports exist of their mechanism of action in insulin resistance, obesity animal models. We investigated the effect of atorvastatin on glucose metabolism and insulin resistance and the mechanism of action in MSG-induced obese mice, a model of T2DM with obesity, hyperinsulinemia, insulin resistance, hyperlipidemia and hyperglycemia [24]. Atorvastatin significantly inhibited the plasma glucose and decreased the plasma insulin level and the HOMA-IR index but increased the ISI in obese mice. These findings suggest that atorvastatin may improve insulin resistance in MSG-induced obese mice.

As mentioned before, mounting evidence indicates that adipose tissue is an important cytokines-secretory organ [25] and that adiposity contributes to a chronic state of systemic inflammation [26]. Actually, the molecular connection between obesity and inflammation was documented in 1993, after the demonstration of enhanced expression of TNF-α in adipose tissue of obese rodents, and more importantly, the amelioration of insulin sensitivity after neutralization of this multi-potent inflammatory cytokine. Inflammatory mediators derived from adipose tissue and increased in level in obesity include IL-6, IL-1β, and monocyte MCP-1 [27, 28]. Further, growing evidence suggests that, similar to TNF-α, these and other inflammatory molecules negatively affect insulin sensitivity through activation of NF-κB, a transcription factor, which triggers the production of numerous inflammatory mediators such as TNF-α and IL-6. These factors can sustain and heighten inflammatory activation, thus leading to local and systemic insulin resistance [29]. In our study, atorvastatin significantly decreased the secretory level of TNF-α and IL-6 in adipose tissue. This finding suggests that atorvastatin may inhibit the generation of inflammatory factors, thereby improving insulin resistance.

Table 5. Effect of atorvastatin on homeostasis model assessment of insulin resistance (HOMA-IR) index and insulin sensitivity index (ISI) in MSG-induced obese mice with insulin resistance. Data are mean±SEM. Mice were treated with atorvastatin for 30 days. n=8 mice/group. *P<0.05, †P<0.01 vs control-treated obese mice.

| Group                  | Fasting blood glucose (mg/dL) | Serum insulin (mIU/L) | ISI (×10⁻⁴) | HOMA-IR |
|------------------------|-------------------------------|-----------------------|-------------|---------|
| Normal non-obese       | 101.8±4.0†                    | 39.6±2.1*c            | 2.6±0.18*c  | 178.8±10.5*i |
| Control                | 135.6±6.1                     | 177.3±34.2            | 0.6±0.11    | 1071.3±225.7 |
| Atorvastatin (80 mg/kg) | 116.8±4.8b                    | 85.0±10.4b            | 1.2±0.20c   | 429.0±55.5b  |

![Figure 4. Effect of atorvastatin on the expression of NF-κB p65 and IκB-α at translational levels in adipose tissue of MSG-induced obese mice with insulin resistance. Mice were treated with atorvastatin (80 mg·kg⁻¹·d⁻¹) for 30 days. Normal: non-obese control mice; MSG: vehicle control-treated obese mice; Atorvastatin: atorvastatin-treated obese mice. The protein expressions of NF-κB p65, IκB-α, and GAPDH were analyzed by Western blot assay (A), the expression levels of NF-κB p65, IκB-α, and GAPDH were normalized to that of GAPDH, respectively. Atorvastatin significantly reduced the expression of NF-κB p65 in adipose tissue compared to MSG group (B), but induced the expression of IκB-α (C). Values are means±SEM as ratio. *P<0.05, †P<0.01 vs normal mice; ‡P<0.05 vs MSG mice.](image-url)
in MSG-induced obese mice.

Furthermore, atorvastatin decreased the mRNA level of TNF-α and IL-6 but not significantly (P=0.08) in adipose tissue, which is consistent with the results of their secretory levels in adipose tissue. In addition, atorvastatin significantly decreased the expression of IKK-β and NF-κB and increased that of the inhibitor of NF-κB, IκB-α. IκB-α is an important kinase that can affect insulin signaling through serine phosphorylation of IRS-1 and by phosphorylation of IκB-α, which leads to stimulation of the NF-κB pathway. IκB-α inhibits the transcriptional activity of NF-κB in the cytoplasm by preventing the nuclear translocation of NF-κB. In the nucleus, it dissociates NF-κB from DNA and transports it back to the cytoplasm. To further support the mechanism of atorvastatin action through inflammatory factors, we analyzed the protein level of NF-κB and IκB-α and found that atorvastatin significantly reduced the level of NF-κB protein and increased protein levels of IκB-α. These findings support our hypothesis that atorvastatin inhibits the activity of IKK-β and NF-κB, and increases that of IκB-α, which inhibits the activity of NF-κB. Thus, atorvastatin reduced inflammatory factor activation and improved insulin resistance in MSG-induced obese mice.

Results from our study and that of others raise questions about the effects in humans being treated with approved doses of atorvastatin. We chose doses of atorvastatin comparable to those used for treatment of hypercholesterolemia in humans. The dose of 80 mg kg⁻¹ d⁻¹ for mice is estimated to be slightly higher than the maximal approved dose for humans. Atorvastatin has a high LD₅₀ (5000 mg/kg) in the mice, so the dose used was safe for the mice in our study. Atorvastatin can adversely affect liver function in some patients with liver dysfunction. In our study, we also assayed AST and ALT levels in serum and found the liver function of MSG-induced obese mice with atorvastatin treatment had no difference from that of the treated control mice (data not shown). Interestingly, we found a decrease in plasma HDL-cholesterol after atorvastatin treatment. This result seems to be conflicting with other reports about the role of increasing HDL with atorvastatin. However, compared to humans, mice and rats transport most of their serum cholesterol in the HDL-C fraction, not the LDL-C fraction. In this mouse model, when atorvastatin decreased the plasma level of total cholesterol, the plasma level of HDL was decreased. However, we have used the mice with MSG-induced obesity as a model of obesity-associated insulin resistance for many years, and many characteristics of this animal model have a striking resemblance to human disease. The most important characteristic of such mice is abdominal obesity. A large amount of abdominal fat in MSG-induced obese mice with insulin resistance could be related to chronic inflammation, so MSG-induced obese mice are suitable for study of the effect of atorvastatin on improving insulin resistance to ameliorate the state of chronic inflammation and inhibit the activity of proteins in the inflammatory pathway.

In conclusion, atorvastatin treatment decreased lipid levels, improved glucose metabolism after glucose loading, and improved insulin resistance in MSG-induced obese mice. Possible mechanisms of the improved glucose metabolism with atorvastatin treatment may include ameliorating the state of chronic inflammation by inhibiting synthesis of inflammatory factors through inhibiting the expression of NF-κB and IKK-β, as well as increasing the expression of IκB-α in adipose tissue.

Acknowledgments

We thank Prof. Ming-zhi XIE for her suggestions about this experimental design.

Author contribution

Ning ZHANG and Zhu-fang SHEN designed research; Ning ZHANG, Yi HUAN, Hui HUANG, Guang-ming SONG and Su-juan SUN performed research; Ning ZHANG analyzed data; Ning ZHANG and Zhu-fang SHEN wrote the paper.

References

1 Bosello O, Zamboni M. Visceral obesity and metabolic syndrome. Obes Rev 2000; 1: 47−56.
2 Christian H, Sophie S, Wolfgang R, Burkhard H, Heiko S, Horst W, et al. Low-grade inflammation, obesity, and insulin resistance in adolescents. J Clin Endocrinol Metab 2007; 92: 4569−74.
3 Koistinen HA, Forsgren M, Wallberg HH, Zierath JR. Insulin action on expression of novel adipose genes in healthy and type 2 diabetic subjects. Obes Res 2004; 12: 25−31.
4 Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473−81.
5 Paz K, Hemi R, LeRaith D, Karasik A, Elhanany H, Kanety H, et al. A molecular basis for insulin resistance: elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxta membrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 1997; 272: 29911−8.
6 Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity induced insulin resistance. Science 1996; 271: 665−8.
7 Tanti JF, Grémeaux T, van Obberghen E, Le Marchand-Brustel Y. Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. J Biol Chem 1994; 269: 6051−7.
8 Hong R, Nir H, Todd RG, Luk VP, Harvey FL. Tumor necrosis factor-α suppresses adipocyte-specific genes and activates expression of adipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappαB activation by TNF-α is obligatory. Diabetes 2002; 51: 1319−36.
9 Prigent M, Barlat I, Langen H, Dargemont C. IκBα and IκBα/NF-κB complexes are retained in the cytoplasm through interaction with a novel partner, RasGAP SH3-binding protein 2. J Biol Chem 2000; 275: 36441−9.
10 Esther L, Mat D. HMG-CoA reductase inhibitors: lipid-lowering and beyond. Drug Discov Today Ther Strateg 2004; 1: 189−94.
11 Wolfgang D, Jozeff D, Matthias F, Hannes FA, Severin PS, Mikko A, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23: 58−63.
12 Macho L, Ficková M, Zezová, Zörad S. Late effects of postnatal administration of monosodium glutamate on insulin action in adult rats. Physiol Res 2000; 49: S79−85.
13 Tokushi K, Fumiaki I, Satoshi M, Koichi H. Gene expression of resistin in adipose tissue and mammary gland of lactating and non-lactating cows. J Endocrinol 2003; 178: R1–R5.
14 Shana S, Zhao BP, Yang JZ. Enhanced muscle by myostatin propeptide increases adipose tissue adiponectin, PPAR-α and PPAR-γ expressions. Biochem Biophys Res Commun 2008; 369: 767–73.
15 Newsholme P, Haber EP, Hirabara SM, Rebelato EL, Procopio J, Morgan D, et al. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol 2007; 583: 9–24.
16 Muoio DM, Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 193–205.
17 Kim JA, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res 2008; 102: 401–14.
18 Engstrom G, Stavenow L, Hedblad B, Lind P, Eriksson KF, Janzon L, et al. Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study. Diabetes 2003; 52: 442–7.
19 Festa A, D’Agostino R Jr, Williams K, Karter AJ, Tracy RP, et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001; 25: 1407–15.
20 Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972–8.
21 Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E745–51.
22 Victor C, Melvin K, Charles R, Cheryl H, Jeffrey T. The genotoxicity profile of atorvastatin, a new drug in the treatment of hypercholesterolemia. Mutat Res 1995; 343: 95–107.
23 Clarke AT, Mills PR. Atorvastatin associated liver disease. Dig Liver Dis 2006; 38: 772–7.
24 Harris WS. n-3 Fatty acids and serum lipoproteins: animal studies. Am J Clin Nutr 1997; 65: 1611S–1616S.